Which companies are Beijing Bohui Innovation Biotechnology's closest peers?

The cockpit's peer set: LongBio Pharma (Suzhou) (1779.HK), Sinotherapeutics (688247.SS), Faeth Therapeutics (FTH), Valneva (VLA.PA), Hvsen Biotechnology (300871.SZ), Liaoning Dingjide Petrochemical (603255.SS), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Beijing Scitop Bio-Tech (300858.SZ).

Is Beijing Bohui Innovation Biotechnology expensive compared with its peers?

On ev / sales it trades at 6.5× against a peer median of 11.2×, 6th cheapest of 16 in its peer set.

How has Beijing Bohui Innovation Biotechnology stock performed?

Over six months to 6 Nov 2026 the shares returned -19.5% against -12.8% for the median peer; over one year -21.6%.

← CockpitCompetitor Analysis › 300318.SZ Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class AOpen in the cockpit ↗

Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class A300318.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum neutral 46

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$553M

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$5.08M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-7.2 pp

WACC 5.0%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥4.51

1D-2.4%

1W+1.4%

1M-12.8%

3M-6.6%

6M-19.5%

YTD-28.1%

1Y-21.6%

ATR %3.9%

52w lowhigh47.7% off high

What Beijing Bohui Innovation Biotechnology does

Employees: 2,170

Beijing Bohui Innovation Biotechnology at a glance

Size Beijing Bohui Innovation Biotechnology (300318.SZ) is a China Health Care company (Biotechnology) with a market value of $553M, the 3623rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.51 on 6 Nov 2026.

Performance Over six months the shares fell 19.5%, against -12.8% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 17 in its peer set.

Growth Revenue grew 6.2% over the last twelve months (peer median -1.8%); the operating margin is -10.8% (peer median -86.7%).

Valuation It trades at 6.5× enterprise value to sales against a peer median of 11.2× (6th cheapest of 16).

Capital Return on invested capital runs 7.2 points below its cost of capital (5.0% WACC).

Relative performance

Six months, rebased to 100: Beijing Bohui Innovation Biotechnology against the median of its 20 peers (local-currency closes).

Beijing Bohui Innovation Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥816M	CN¥820M	CN¥848M	CN¥1.04B	CN¥792M
Revenue growth	—	-3%	-19%	+31%	—
Gross profit	CN¥243M	CN¥269M	CN¥350M	CN¥379M	CN¥174M
EBITDA	CN¥27.4M	CN¥69.3M	CN¥173M	CN¥175M	CN¥14.2M
Net income	-CN¥88.8M	-CN¥91.9M	CN¥9.25M	-CN¥24.9M	-CN¥78.4M
Free cash flow	-CN¥252M	-CN¥292M	-CN¥227M	-CN¥60.5M	-CN¥121M
Capital expenditure	CN¥127M	CN¥157M	CN¥189M	CN¥198M	CN¥161M
Total debt	CN¥931M	CN¥1.13B	CN¥1.06B	CN¥814M	CN¥794M

Quarterly statements and history in the cockpit →

Beijing Bohui Innovation Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Beijing Bohui Innovation Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Bohui Innovation Biotechnology is the large dot.

Beijing Bohui Innovation Biotechnology competitors and peer comparison

How Beijing Bohui Innovation Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Bohui Innovation Biotechnology against its 20 peers (data as of 6 Nov 2026)
Measure	300318.SZ	Peer median	Rank in peer set
1-month return	-12.8%	-12.7%	11th highest of 21
6-month return	-19.5%	-12.8%	6th lowest of 17
Distance from 52-week high	-47.7%	-44.9%	9th lowest of 21
Revenue growth (TTM)	+6.2%	-1.8%	5th highest of 15
Operating margin	-10.8%	-86.7%	7th highest of 16
EV / Sales	6.5×	11.2×	6th cheapest of 16
ROIC minus cost of capital	-7.2 pp	-10.6 pp	7th highest of 13
Net debt / EBITDA	29.0×	n/a	—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Beijing Bohui Innovation Biotechnology 300318.SZ	China	$553M	-19%	+6%	-11%	6.5×	n/a	n/a
LongBio Pharma (Suzhou) 1779.HK	Hong Kong	$554M	n/a	n/a	n/a	n/a	n/a	n/a
Sinotherapeutics 688247.SS	China	$537M	-14%	-17%	0%	7.0×	31.6%	+7.0%
Faeth Therapeutics FTH	United States	$570M	-6%	n/a	n/a	n/a	n/a	n/a
Valneva VLA.PA	France	$534M	-2%	-27%	-87%	4.0×	n/a	n/a
Hvsen Biotechnology 300871.SZ	China	$531M	-33%	+2%	17%	2.2×	n/a	n/a
Liaoning Dingjide Petrochemical 603255.SS	China	$530M	-15%	+70%	5%	5.4×	n/a	n/a
Alebund Pharmaceuticals (Jiangsu) 9637.HK	Hong Kong	$576M	n/a	+674%	-495%	25.7×	n/a	n/a
Beijing Scitop Bio-Tech 300858.SZ	China	$526M	-25%	+4%	8%	8.0×	n/a	n/a
Climb Bio CLYM	United States	$591M	-10%	n/a	n/a	n/a	n/a	n/a
Genfit GNFT.PA	France	$593M	+19%	+28%	-130%	11.2×	40.0%	+143.5%
HanchorBio 7827.TW	Taiwan	$511M	n/a	n/a	-225%	48.0×	n/a	n/a
Shanghai Serum Bio-Technology 688163.SS	China	$507M	-11%	-1%	26%	13.7×	n/a	n/a
Neurogene NGNE	United States	$506M	-18%	-100%	n/a	n/a	n/a	n/a
DiaMedica Therapeutics DMAC	United States	$505M	+48%	n/a	n/a	n/a	n/a	n/a
Berry Genomics 000710.SZ	China	$504M	-5%	-2%	-24%	3.8×	n/a	n/a
Qurient 115180.KS	South Korea	$503M	-59%	-20%	-517%	98.9×	n/a	n/a
Crescent Biopharma CBIO	United States	$503M	-28%	n/a	-1,418%	28.3×	n/a	n/a
Ascletis Pharma 1672.HK	Hong Kong	$610M	-73%	-59%	-71,976%	2,088.7×	n/a	n/a
Apnimed APMD	United States	$629M	n/a	+380%	-140%	20.3×	n/a	n/a
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%

Questions

Which companies are Beijing Bohui Innovation Biotechnology's closest peers?: The cockpit's peer set: LongBio Pharma (Suzhou) (1779.HK), Sinotherapeutics (688247.SS), Faeth Therapeutics (FTH), Valneva (VLA.PA), Hvsen Biotechnology (300871.SZ), Liaoning Dingjide Petrochemical (603255.SS), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Beijing Scitop Bio-Tech (300858.SZ).
Is Beijing Bohui Innovation Biotechnology expensive compared with its peers?: On ev / sales it trades at 6.5× against a peer median of 11.2×, 6th cheapest of 16 in its peer set.
How has Beijing Bohui Innovation Biotechnology stock performed?: Over six months to 6 Nov 2026 the shares returned -19.5% against -12.8% for the median peer; over one year -21.6%.